reports
Trivago NV: 1 director
A director at Trivago NV sold 10,374 shares at 2.419USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
- Martin Marandon-Carlhian
- Stephane Houri
Elmos Semiconductor SE : Solid Q1 2024 results, FY 2024 reiterated
>Strong Q1 2024 results - This morning, Elmos reported Q1 2024 results that beat expectations. Revenues were € 136.8m, above the consensus at € 135.4m. They were up 4.5% y-o-y but down 13% q-o-q. EBIT came in at € 33.8m, giving an EBIT margin of 24.7% above the consensus at € 31.7m and 23.4%. EPS was € 1.44 above consensus at € 1.27. Adjusted free cash flow stood at -€ 48.9m (vs € 35m in Q4 2023) impacted by year-end effects on working capital. Capex came in at € 20.3...
- Martin Marandon-Carlhian
- Stephane Houri
Elmos Semiconductor SE : Solid Q1 2024 results, FY 2024 reiterated
>Strong Q1 2024 results - This morning, Elmos reported Q1 2024 results that beat expectations. Revenues were € 136.8m, above the consensus at € 135.4m. They were up 4.5% y-o-y but down 13% q-o-q. EBIT came in at € 33.8m, giving an EBIT margin of 24.7% above the consensus at € 31.7m and 23.4%. EPS was € 1.44 above consensus at € 1.27. Adjusted free cash flow stood at -€ 48.9m (vs € 35m in Q4 2023) impacted by year-end effects on working capital. Capex came in at € 20.3...
- Maria Vara
- Valliant Campagne
Medios: EBITDA hit by price regulations, reiterates outlook
Medios reported Q1 2024 results with revenue increasing 5.8% to EUR 456.2m led by 8.9% growth coming from the Pharmaceutical Supply (PS) segment, of which sales amounted to EUR 401m (EUR 368.1m), while the Patient-Specific Therapies (PTS) segment suffered from the 12.4% decline due to the divestmen
- Maria Vara
BICO: profitability impacted by mixed sales in Q1 2024; CMD in Septemb...
BICO has reported Q1 2024 net sales amounting to SEK 510.3m (+2% vs. css) implying 4.4% YoY growth and organic growth of 4.7% (-1.1%). The Biosciences segment outperformed with net sales showing 36.3% organic growth to SEK 310m (SEK 230m), while Bioprinting and Bioautomation fell short of expectati
- Oliver Metzger
Coloplast : Q2 review – Top and bottom line a slight miss, focus on LC...
>Q2 review – Miss on top and bottom line - Coloplast’s Q2 2024 revenues of DKK 6,586m (+8.7% y-o-y) were -1%/-2% vs ODDO BHF/consensus, driven by organic growth of 8% (7.3%/7.6% ODDO BHF/consensus). External growth contributed to the tune of 4% and forex created a headwind of 300bp. Coloplast achieved an EBIT of DKK 1,772m (+7.3% y-o-y, margin 26.9%), which was -3%/-4% vs expectations. Profitability was supported by operating leverage and efficiency savings but impact...
Syngenta extends leadership in fungicides with ADEPIDYN® technology
Syngenta Group / Key word(s): Miscellaneous Syngenta extends leadership in fungicides with ADEPIDYN® technology 07.05.2024 / 09:00 CET/CEST ADEPIDYN® technology on track to be first of Syngenta’s crop protection active ingredients to attain billion-dollar annual sales within eight years of commercialization Following registration approval in Great Britain, farmers in more than 55 countries now have access to this powerful fungicide Success reflects Syngenta’s innovation leadership in fungicides and the SDHI mode of action, and in bringing to market products with strong su...
EQS-News: Biotest steigert Umsatz im ersten Quartal 2024 um 83,6% auf ...
EQS-News: Biotest AG / Schlagwort(e): Quartalsergebnis Biotest steigert Umsatz im ersten Quartal 2024 um 83,6% auf 215,2 Mio. Euro 07.05.2024 / 09:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PRESSEMITTEILUNG Biotest steigert Umsatz im ersten Quartal 2024 um 83,6% auf 215,2 Mio. Euro Umsatz mit Produkten stieg um 17,7 % auf 138,0 Mio. Euro EBIT gesteigert auf 52,8 Mio. Euro Fibrinogenstudie erfolgreich abgeschlossen Dreieich, 07. Mai 2024. Im ersten Quartal des Geschäftsjahres 2024 verzeichnete die Biotest Gr...
EQS-News: Biotest increased sales by 83.6% to Euro 215.2 million in fi...
EQS-News: Biotest AG / Key word(s): Quarter Results Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024 07.05.2024 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024 Product sales increased by 17.7% to Euro 138.0 million EBIT increased to Euro 52.8 million Successful completion Fibrinogen study Dreieich, 07 May 2024. The Biotest Group recorded revenue of € 215.2 million in the first quarter of the 202...
- Hilde Van Boxstael
- Sharad Kumar S.P
- Wim Hoste
- Wim Lewi
- Paul de Froment
- Sebastián Marroquin Mérida
- Thomas Mordelle
HydrogenPro: Awaiting deliveries to Salzgitter and additional orders
Today, HydrogenPro reported Q1 2024 results which reflect slower activity than in previous quarters, with revenue of just NOK4m in Q1 2024 vs NOK83m in Q1 2023, NOK127m in Q4 2023 and cons. at NOK11m. As expected, revenues were impacted by the transition from the completion of ACES (US) and prepara
- Bruno Duclos
- Eva Olejniczak
- Stéphane Afonso
- ABGSC Renewable Energy Research
- Haakon Amundsen
- Stian Wibstad
- Delphine Brault
- Quentin Borie
Geberit AG : Q1 brings an upward surprise, notably at the activity lev...
>Q1 2024: a limited decline in sales (-1.4% l-f-l) and the margin - The group reported this morning Q1 results above forecasts. Sales were down 1.4% at constant forex (consensus -4.0%). The group stated that volumes had fallen by 2%, while price hikes contributed around 1% to growth. Above all, it indicated that this stronger resilience than expected in sales is largely due to restocking at wholesalers, while demand remains clearly down. The EBITDA margin reached 32.8...
Manhattan Unified Supply Chain Powers Schneider Electric’s Global Dist...
LONDON--(BUSINESS WIRE)-- Manhattan Associates Inc. (NASDAQ: MANH) today announced that leading global energy management and industrial automation organisation, has chosen and to supercharge its global distribution and transportation network as part of an ongoing business-wide transformation strategy. Manhattan Active® Supply Chain (the combination of Manhattan Active WM and Manhattan Active TM) will be implemented in over 20 distribution centres and Schneider Electric plans to deploy Manhattan Active TM across a further 200+ operational sites. Unifying both warehouse and transportation t...
Pearson to Debut Generative AI Study Tools to University Students Inte...
LONDON--(BUSINESS WIRE)-- (FTSE: PSON.L) today announced that it will expand its generative AI beta study tools into global editions of its leading higher education titles, making the tools available to tens of thousands of students across Australia, Asia-Pacific, Canada, the Middle East, and Europe by August 2024. Pearson began integrating generative AI study tools into its products and content in the US last August. This press release features multimedia. View the full release here: Campbell Biology GE (Photo: Business Wire) Pearson’s AI beta study tools will expand to dozens of English-la...
Icelandic Salmon AS – Notice of Annual General Meeting 2024
Icelandic Salmon AS – Notice of Annual General Meeting 2024 Bíldudalur, 7th of May The annual general meeting of Icelandic Salmon AS (the "Company") will be held on 21 May 2024 at 11:00 (CEST). Please find the notice including appendices enclosed. The documents are also made available on the Company's website . For more information, please contact: Björn Hembre, CEO. Tel: This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments ...
Change in the publishing date of Suominen’s Interim Report for January...
Change in the publishing date of Suominen’s Interim Report for January-September 2024 Suominen Corporation's stock exchange release on May 7, 2024 at 10:00 a.m. EEST Suominen will publish its Interim report for January-September 2024 on Wednesday November 6, 2024 approximately at 9.30 a.m. (EET). Earlier the company announced that it would publish its Interim report for January-September 2024 on Tuesday October 29, 2024. SUOMINEN CORPORATION For more information: Emilia Peltola, VP, Communications and Sustainability, tel. +358 10 214 3082 Suominen manufactures nonwovens as roll goods fo...
Suomisen vuoden 2024 tammi-syyskuun osavuosikatsauksen julkistuspäivä ...
Suomisen vuoden 2024 tammi-syyskuun osavuosikatsauksen julkistuspäivä muuttuu Suominen Oyj:n pörssitiedote 7.5.2024 klo 10.00 Suominen julkistaa vuoden 2024 tammi-syyskuun osavuosikatsauksensa keskiviikkona 6.11.2024 noin klo 9.30. Aiemmin yhtiö ilmoitti julkaisevansa tammi-syyskuun osavuosikatsauksensa tiistaina 29.10.2024. SUOMINEN OYJ Lisätietoja: Emilia Peltola, viestintä- ja vastuullisuusjohtaja p. 010 214 3082 Suominen valmistaa kuitukankaita rullatavarana pyyhintätuotteisiin sekä muihin sovelluksiin. Visiomme on olla edelläkävijä innovatiivisissa ja vastuullisissa kui...
Rush Factory Oyj - Liiketoimintakatsaus 1.1.-31.3.2024
Rush Factory Oyj - Liiketoimintakatsaus 1.1.-31.3.2024 Rush Factory Oyj 7.5.2024 klo 10.00 Yhtiötiedote Ensimmäisellä kvartaalilla ei tänä vuonna järjestetty tapahtumia joten liikevaihtoa ei kertynyt raportointikauden aikana (2023: 0,304 miljoonaa euroa). Kuluvan kauden ensimmäinen tapahtuma järjestettiin Hampurissa 13.5.2024. Lipunmyynti ensimmäisen kvartaalin aikana oli yhteensä 0,930 miljoonaa euroa (2023: 1,492). Kaudelle 2024 kalenterissa on yhteensä 23 Color Obstacle Rush -tapahtumaa kun viime vuonna niitä järjestettiin 26. Toimitusjohtaja Mika Metsämäki: “Saks...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.